StemCell Therapy

Editors note: The Salt Lake Tribune is providing free access to critical stories about the coronavirus. Sign up for our Top Stories newsletter, sent to your inbox every weekday morning. To support journalism like this, please donate or become a subscriber.

The state recorded another 499 confirmed cases of COVID-19, the Utah Department of Health announced Wednesday with one more Utahn dying from the disease.

A Salt Lake County man, between ages 65 and 84 and in a hospital, was the latest person in Utah to die from COVID-19, UDOH reported. His death brings the states toll due to the coronavirus to 173 people.

Another 32 people were hospitalized with COVID-19, according to the state report. There were 194 people hospitalized in Utah as of Tuesday (hospitalization figures are a day behind case counts), and there have been 1,476 Utahns hospitalized with COVID-19 since the first cases were reported in March.

Wednesdays new cases bring the states total number of cases to 22,716. Of those, 12,707 are considered recovered meaning, by the states definition, its been three weeks since they were diagnosed and theyre still alive.

Another 2,605 tests were administered Wednesday, bringing the total number of Utahns tested to 343,358. The rate of positive tests for the last seven days is 11.8%, and its at 6.6% since the first cases were reported in March.

The state has averaged 561.7 cases per day in the last week. Thats well above the 200-cases-per-day average the states epidemiologist, Dr. Angela Dunn, said in an internal memo last month would be necessary by July 1 for the state to avoid a complete shutdown of the states economy.

Also Wednesday, researchers at the University of Utah announced the latest results from the Utah HERO study, measuring the spread of COVID-19 in Utah.

Counting nearly 9,000 residents in Davis, Salt Lake, Summit and Utah counties, the studys first phase found about 1% tested positive for COVID-19 antibodies. The results match the preliminarily findings, announced Friday in a webinar.

Antibody tests are a lagging indicator, showing more of where the virus has been than where its going, said Dr. Stephen Alder, the Utah HERO studys director of field operations and a professor in the U.s Department of Family and Preventative Medicine.

Were looking a few weeks in the past, when were looking at antibodies, Alder said. Its a good historical marker.

The second wave of the study will expand past the four counties measured in the first phase, into hot spots of viral activity that were going to go into and understand those areas better, Alder said.

Originally posted here:
Utah tallies another 499 cases of COVID-19, and one more death - Salt Lake Tribune

Geneva/London The World Health Organization has updated its account of the early stages of the COVID-19 crisis to say it was alerted by its own office in China, and not by China itself, to the first pneumonia cases in Wuhan.

The U.N. health body has been accused by U.S. President Donald Trump of failing to provide the information needed to stem the pandemic and of being complacent towards Beijing, charges it denies.

On April 9, WHO published an initial timeline of its communications, partly in response to criticism of its early response to the outbreak that has now claimed more than 521,000 lives worldwide.

In that chronology, WHO had said only that the Wuhan municipal health commission in the province of Hubei had on Dec. 31 reported cases of pneumonia. The U.N. health agency did not, however, specify who had notified it.

WHO chief Tedros Adhanom Ghebreyesus told a news conference on April 20 that the first report had come from China, without specifying whether the report had been sent by Chinese authorities or another source.

But a new chronology, published this week by the Geneva-based institution, offers a more detailed version of events.

It indicates that it was the WHO office in China that on Dec. 31 notified its regional point of contact of a case of viral pneumonia after having found a declaration for the media on a Wuhan health commission website on the issue.

The same day, WHOs epidemic information service picked up another news report transmitted by the international epidemiological surveillance network ProMed based in the United States about the same group of cases of pneumonia from unknown causes in Wuhan.

After which, WHO asked the Chinese authorities on two occasions, on Jan. 1 and Jan. 2, for information about these cases, which they provided on Jan. 3.

WHO emergencies director Michael Ryan told a news conference Friday that countries have 24-48 hours to officially verify an event and provide the agency with additional information about the nature or cause of an event.

Ryan added that the Chinese authorities immediately contacted the WHO as soon as the agency asked to verify the report.

WHO chief Tedros Adhanom Ghebreyesus told a news briefing that the organization should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients. | AFP-JIJI

Trump has announced that his country, the main financial contributor to WHO, will cut its bridges with the institution, which he accuses of being too close to China and of having poorly managed the pandemic.

The WHO denies any complacency toward China.

Also Friday, Tedros told a news briefing that the WHO should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients.

Nearly 5,500 patients in 39 countries have so far been recruited into the Solidarity trial, he said, referring to clinical studies the U.N. agency is conducting.

We expect interim results within the next two weeks.

The Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: standard care; remdesivir; the anti-malaria drug touted by Trump, hydroxychloroquine; the HIV drugs lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

Earlier this month, it stopped the arm testing hydroxychloroquine, after studies indicated it showed no benefit in those who have the disease, but more work is still needed to see whether it may be effective as a preventative medicine.

Ryan, the WHOs emergencies program chief, said it would be unwise to predict when a vaccine could be ready against COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than half a million people.

While a vaccine candidate might show its effectiveness by years end, the question was how soon it could be mass produced, he told the U.N. journalists association ACANU in Geneva.

There is no proven vaccine against the disease now, while 18 potential candidates are being tested on humans.

WHO officials defended their response to the virus that emerged in China last year, saying they had been driven by the science as it developed. Ryan said what he regretted was that global supply chains had broken, depriving medical staff of protective equipment.

WHO emergencies director Michael Ryan | Pool via REUTERS

I regret that there wasnt fair, accessible access to COVID tools. I regret that some countries had more than others, and I regret that front-line workers died because of (that), he said.

He urged countries to get on with identifying new clusters of cases, tracking down infected people and isolating them to help break the transmission chain.

People who sit around coffee tables and speculate and talk (about transmission) dont achieve anything. People who go after the virus achieve things, he said.

On the sidelines ACANU briefing, another top WHO official said almost 30 percent of genome sequencing data from samples of the COVID-19 virus collected by the body have shown signs of mutation, but there is no evidence this has led to more severe disease.

I think its quite widespread, said Soumya Swaminathan, WHO chief scientist.

The U.N. agency has so far collected 60,000 samples of the disease, she said.

Scientists at Scripps Research this month found that by April the mutated virus accounted for some 65 percent of cases submitted from around the world to a major database.

The genetic mutation in the new coronavirus, designated D614G, significantly increases its ability to infect cells and may explain why outbreaks in northern Italy and New York were larger than ones seen earlier in the pandemic, they found in a study.

Maria Van Kerkhove, technical lead on the COVID-19 pandemic at the WHO, said at Fridays briefing the mutated strain had been identified as early as February and had been circulating in Europe and the Americas.

So far, there is no evidence it leads to more severe disease, she said.

Go here to read the rest:
WHO says it was first alerted to coronavirus by its office, not China - The Japan Times

As Canada continues to reopen, some grocery stores, salons and other businesses have implemented temperature screening an approach that uses a touchless scanner to measure a persons body temperature in an attempt to prevent the spread of the novel coronavirus.

The process was made mandatory for all air travellers in Canada in mid-June. Any passenger who shows a fever on two measurements, taken 10 minutes apart, will be asked to rebook after 14 days.

However, some experts wonder whether the step is effective given a person can shed the COVID-19 virus without having a fever or any change in body temperature. The tool often used to measure temperature has also been shown to be unreliable.

READ MORE: Temperature screening not always reliable to mitigate coronavirus risk, experts say

For those reasons, temperature screening has not been recommended by Canadas chief public health officer Theresa Tam. In fact, she quickly shut down the approach when more businesses began implementing the practice in May.

The more you actually understand this virus, the more you begin to know that temperature-taking is not effective at all, Tam said in a ministerial update that month.

Tam said the likelihood of screening someone who was symptomatic was relatively inefficient in comparison to those who were asymptomatic.

If we have a significant number of asymptomatic or pre-symptomatic people, that also even reduces the effectiveness even more.

Dr. Susy Hota, the medical director of the Infection Prevention and Control and Medical Device Reprocessing department at the University Health Network in Toronto, agrees.

There really are a lot of limitations to temperature checks, and Im not really convinced that theyre worth investing in for this purpose, Hota said.

READ MORE: Canada to screen air travellers for fever amid coronavirus pandemic: Trudeau

There are also inaccuracies with the temperature probes used for this purpose, Hota said.

She worries they can give patrons and business owners a false sense of security.

Temperature screening is typically not an effective way to detect COVID-19 when used on its own, and thats because of the way the virus spreads.

When we talk about the issue of pre-symptomatic shedding and transmission, were talking about people who have no symptoms yet so no fever, Hota said.

Once youve developed the fever, we know what were dealing with but in the pre-symptomatic phase, a temperature check wont help.

Problems can also arise from the touch-less temperature probes currently being used in airports, grocery stores and by other businesses.

Its a variable that isnt infallible, said Dr. Leighanne Parkes, infectious disease specialist and microbiologist at the Jewish General Hospital in Montreal.

It depends on the instrument that were using, the ambient temperature, (if) the instrument is calibrated correctly, is the individual coming in from a hot outside or a cold outside?

All these things come into play when a temperature probe is used, making true measures hard to come by.

READ MORE: You might be wearing your mask, gloves wrong. How to use PPE properly

There are also other reasons a persons body temperature could be elevated that dont have to do with COVID-19.

Medication, certain pre-existing conditions, weather and what you were doing immediately prior to having your temperature checked are all factors that can affect your body temperature, Hota said.

It is possible that your ambient temperature and what you were doing before might register a higher temperature than you really would have otherwise, she said.

However, Parkes believes temperature screening could be helpful when its bundled with other preventative health measures.

If you have an adequately calibrated machine, youre indoors using appropriate techniques and youre also symptom-screening for things that are not fever, and risk factors including contact, those altogether can pick up some of the most high-risk cases, Parkes said.

Temperature screening should be considered just one layer in a pyramid of prevention, she said.

Its not a replacement for the other means that we have in place, such as social distancing, masking in public spaces, adequate ventilation, adequate environmental cleaning all those things combined.

Although temperature screening may not accurately detect COVID-19, its still within the rights of a business to deny you service on the grounds of a high temperature.

This is because employers and employees have the right to a safe working environment.

You cant be denied entry on grounds of race or religion because thats discrimination, but if your temperature is above some arbitrary scale, then you can be denied entry, said Bernard Dickens, professor emeritus of health law and policy in the faculty of law, faculty of medicine and Joint Centre for Bioethics at the University of Toronto.

READ MORE:Planes, salons and grocery stores: Companies that require masks in Canada

Its a security ground to protect the staff who work in the facility. They have a right to a safe working environment, and the store is responsible for the safety of its employees.

Basically, any business can make conditions for who they serve as long as they dont discriminate in violation of the human rights code.

For this reason, you can refuse to take a temperature test, but the store can refuse your entry upon doing so.

You have no right to go into the store because the store can set reasonable conditions , Dickens said.

Questions about COVID-19? Here are some things you need to know:

Symptoms can include fever, cough and difficulty breathing very similar to a cold or flu. Some people can develop a more severe illness. People most at risk of this include older adults and people with severe chronic medical conditions like heart, lung or kidney disease. If you develop symptoms, contact public health authorities.

To prevent the virus from spreading, experts recommend frequent handwashing and coughing into your sleeve. They also recommend minimizing contact with others, staying home as much as possible and maintaining a distance of two metres from other people if you go out.

In situations where you cant keep a safe distance from others, public health officials recommend the use of a non-medical face mask or covering to prevent spreading the respiratory droplets that can carry the virus.

For full COVID-19 coverage from Global News, click here.

With files from Global News Emerald Bensadoun

Meghan.Collie@globalnews.ca

2020Global News, a division of Corus Entertainment Inc.

See the original post here:
Can I refuse a temperature check? What to know about the COVID-19 screening tool - cjoy.com

Camel milk is converted into powder form to preserve it for a longer time period. Camel milk powder has high levels of iron, protein, and vitamin C, and less fat. Apart from being rich in nutrients, camel milk powder is used as a potential preventative medicine for diabetes. According to the studies conducted by some researchers in Bikaner, Rajasthan, camel milk has sufficient levels of insulin, which can help prevent and even treat type 1 and type 2 diabetes. Camel milk powder helps in providing immunity due to its high levels of proteins and other organic compounds. Since many of these compounds have antimicrobial properties, the consumption of camel milk can improve human health by boosting the immune system.

Request Sample Copy of Camel Milk Powder Market: https://www.premiummarketinsights.com/sample/TIP00028161

Key Players:

After studying key companies, the report focuses on the startups contributing towards the growth of the market. Possible mergers and acquisitions among the startups and key organizations are identified by the reports authors in the study. Most companies in the Camel Milk Powder market are currently engaged in adopting new technologies, strategies, product developments, expansions, and long-term contracts to maintain their dominance in the global market.

Analysis tools such as SWOT analysis and Porters five force model have been inculcated in order to present a perfect in-depth knowledge about Camel Milk Powder market. Ample graphs, tables, charts are added to help have an accurate understanding of this market. The Camel Milk Powder market is also been analyzed in terms of value chain analysis and regulatory analysis.

Avail Discount on this [emailprotected]: https://www.premiummarketinsights.com/discount/TIP00028161

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Risk Assessment for Investing in Global Market

Critical Success Factors (CSFs)

The competitive landscape of the market has been examined on the basis of market share analysis of key players. Detailed market data about these factors is estimated to help vendors take strategic decisions that can strengthen their positions in the market and lead to more effective and larger stake in the global Camel Milk Powder market. Pricing and cost teardown analysis for products and service offerings of key players has also been undertaken for the study.

Table of Contents:

1 Executive Summary

2 Preface

3 Camel Milk Powder Market Overview

4 Market Trend Analysis

5 Global Camel Milk Powder Market Segmentation

6 Market Effect Factors Analysis

7 Market Competition by Manufacturers

8 Key Developments

9 Company Profiling

About Premium market insights:

Premiummarketinsights.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Sameer Joshi Call: US: +1-646-491-9876, Apac: +912067274191Email: [emailprotected]

Follow this link:
Camel Milk Powder Market 2027 COVID-19 Impact and Global Analysis by Type (Full Cream Milk Powder, Skimmed Milk Powder); Application (Infant formula,...

Goldman Pharmaceutical Group announces the creation of the only FDA registered over-the-counter pet medicines available online and without a prescription, Pet OTC. Treating animals suffering from motion sickness, digestive issues and emotional distress.

NEW YORK, July 7, 2020 /PRNewswire/ -- Goldman Pharmaceutical Group announces that its full lineup of over-the-counter pet medications include: NausX, an anti-emetic medication designed for dogs with motion sickness which include nausea, dizziness and vomiting; Calmatrol, an anti-histamine medication designed to relieve dogs in stress related circumstances bringing instant relief to your dog; and DIFIXN, an anti-diarrheal treatment designed to relieve dogs with diarrhea.

American Pet Products Association (APPA) announced in February of this year that the U.S. is expected to reach a record 100 billion in sales for pet products and services. The CEO, Steve King of the American Pet Products Association (APPA), reported that U.S. sales of pet products and services are nearing $100 billion for the first time, as 2019 spending reached $95.7 billion. The announcement came during Global Pet Expo, the largest annual pet products trade show presented by APPA and the Pet Industry Distributors Association (PIDA). APPA's pet industry expenditures encompass spending in four major categories: Pet Food & Treats; Supplies, Live Animals & OTC (over-the-counter) Medicine; Vet Care & Product Sales; and Other Services.

"Scientific research from the Human Animal Bond Research Institute (HABRI) shows that when you invest in your pets' health, you're investing in your own health," said King. "Improved physical health and reduced feelings of loneliness and social isolation are just a few of the health benefits you're likely to experience by owning a pet."

Goldman Pharmaceutical Group understands that motion sickness in dogs is a common problem before you know it, your furry best friend's breakfast can end up all over your backseat!

NausX by Pet OTC is the ultimate treatment for canine motion sickness. It's a powerful preventative when taken before a trip, and a fast-acting remedy to treat sudden symptoms immediately. Some of the signs and symptoms of motion sickness in dogs include:

Goldman Pharmaceutical Group created Calmatrol as a calming formula that reduces anxiety and stress in dogs and puppies for a much more confident and relaxed pet. Calmatrol by Pet OTC will soothe anxious dogs and alleviate symptoms of:

The Calmatrol treatment by Pet OTC is formulated to encourage canine calmness android behavior, while helping your fury friend overcome feelings of nervousness, agitation and aggression.

The last of the over-the-counter pet treatments manufactured by Goldman Pharmaceutical Group is Difixn by Pet OTC an anti-diarrheal treatment that works fast to relieve dogs of the symptoms of Diarrhea.

Pet OTC Products:

Associated Press American Pet Products Association (APPA) press release cited, visit https://apnews.com/4b4705fc9bc1cdd6f3f951af2d3cd63d for more information.

About American Pet Products Association (APPA)

The American Pet Products Association is the leading trade association serving the interests of the pet products industry since 1958. APPA membership includes more than 1,100 pet product manufacturers, their representatives, importers and livestock suppliers representing both large corporations and growing business enterprises. APPA's mission is to promote, develop and advance pet ownership and the pet product industry and to provide the services necessary to help its members prosper. APPA is also proud to grow and support the industry through the following initiatives: Pets Add Life (PAL), Tony La Russa's Animal Rescue Foundation (ARF) Pets and Vets Program, the Human Animal Bond Research Institute (HABRI), the Pet Industry Joint Advisory Council (PIJAC), Bird Enjoyment and Advantage Koalition (BEAK), and the Pet Care Trust. Visit http://www.americanpetproducts.org for more information.

About Goldman Pharmaceutical Group (GPG)

Goldman Pharmaceutical Group is concerned with the overall health and well being of people and animals. GPG develops and markets products dedicated to human and animal health and safety. The company markets disinfectants, diagnostic test kits to detect viral bacteria, allergens, teeth and oral care, fungal nail treatments, acne skincare, luggage technology, pet food, pet wellness aids, and over-the-counter pet treatments. Goldman Pharmaceutical Group is a leader in contract manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, wound care and disinfectants.

GPG started as a pharmaceutical repacking company focusing mainly on private labeling. Their mission is to continuously innovate and bring new products to market within the medical and pharmaceutical industries, while upholding and creating strong relationships with their clientele and the public. Visit http://goldmanpharma.com/ for more information. Exclusive Manufacturer and Distributor for Pet OTC Products.

Contact Information for Goldman Pharmaceutical Group and Pet OTC:Jeff Magsitzajeff@goldmanpharma.comwww.petsotc.com

Media Contact:Annamarie Seabright, PublicistSignature |PRA Public Relations & Digital Marketing Agency in California and New Yorkannamarie@SignaturePR.presswww.SignaturePR.press

View original content to download multimedia:http://www.prnewswire.com/news-releases/us-pet-products-and-services-are-expected-to-reach-100-billion-in-sales-for-2020-the-over-the-counter-pet-meds-are-a-huge-percentage-of-consumer-spending-301088845.html

SOURCE Goldman Pharmaceutical Group

View post:
US Pet Products and Services are Expected to Reach 100 Billion in Sales for 2020, the Over-the-Counter Pet Meds are a Huge Percentage of Consumer...

Tuesday, June 30, 2020 3:17 a.m. EDT by Thomson Reuters

By Kate Kelland

LONDON (Reuters) - A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.

The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus.

TheCOPCOVstudy was paused pending review after the treatment trial results.

It is a randomised, placebo-controlled trial that is aiming to enrol 40,000healthcare workers and other at-risk staffaround the world, and is being led by the Oxford University's Mahidol Oxford Tropical Medicine Research Unit(MORU) in the Thai capital, Bangkok.

U.S. President Donald Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself, even after the U.S. regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

The FDA later revoked emergency use authorisation for the drugs to treat COVID-19, after trials showed they were of no benefit as treatments.

But White, who is co-leadng the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.

"Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomised controlled trial," he said in a statement. "The question whether (it) can prevent COVID-19 or not remains as pertinent as ever."

White's team said recruitment of British health workers would resume this week, and said plans were under way for newsites in Thailand and Southeast Asia,Africa and South America.Results are expected by the end of this year.

(Reporting by Kate Kelland, editing by Paul Sandle and Timothy Heritage)

Read more:
Global COVID-19 prevention trial of hydroxychloroquine to resume - WNWN-FM

Launches First-in-Kind Reimbursed Virtual Fitness Program for GO365 Members

NEW YORK, June 29, 2020 /PRNewswire/ --Virtual Health Partners (VHP), an innovator in cost-effective virtual health and wellness solutions, and Gold's Gym, the world's trusted fitness authority, today announce the launch of their highly comprehensive live virtual fitness and nutrition programming and on-demand services to members ofGO365, a Humana brand, powered by Concierge Health's Connected Ecosystem.

VHP empowers and incentivizes GO365 members to become more active and take control of their health and fitness goals by tracking participation and progress to achieve rewards.

In partnership with Gold's Gym, VHP streamlines the home workout process by granting members exclusive on-demand classes, live workouts, nutrition, training tips, progress tracking, accountability groups, and 24/7 access to Gold's Gym fitness experts. This virtual system fills in the gaps that are left by the new regulations imposed on the fitness industry by COVID-19, providing a sense of community many people need to stay inspired and motivated."

"This pandemic has accelerated the need to provide consumers a fully omnichannel fitness and wellness offering, both in our clubs and at home," shares Adam Zeitsiff, President & CEO of Gold's Gym. "Virtual Health Partners enables us to deliver world-class fitness, training, and class variety that Gold's Gym is known for the last 50+ years, straight into GO365's member's home. Leveraging Concierge Health's ecosystem, we can provide an end to end solution making data collection from the home seamless for the members to receive their reward benefits."

"Our model provides a scalable and customizable solution to fit any of our partners' needs all thru a turnkey HIPAA and Privacy compliant platform," states Jillian Bridgette Cohen, VHP Co-Founder, and CEO. "Our extensive understanding across multiple sectors has enabled us to build broad integration capabilities within the marketplace, which, in partnership with Gold's Gym, has allowed us to help merge the fitness, medical, and insurance industry cohesively."

GO365 members can get started by going to https://virtualhealthpartners.com/go365golds/to get registered and started.

AboutVirtual Health PartnersVirtual Health Partners (VHP) is an innovator in cost-effective health and wellness, focusing on live, virtual nutrition, fitness and lifestyle modification within a contained ecosphere of support. Offered exclusively through networks of participating partners including insurers, hospital systems, physicians, corporations, pharmaceutical, medical device, fitness and nutrition companies, VHP's Business-to-Business-to-Consumer (B2B2C) model provides a SaaS and PaaS solution that is scalable and can be white labeled to fit partners' needs. Through the private, HIPAA compliant platform, VHP provides its partners with a turnkey solution for clients in the areas of weight loss and weight loss procedures, metabolic syndrome, oncology, women's health, digestive diseases, cardiac rehab, preventative medicine, plastic surgery and general wellness.www.virtualhealthpartners.com

About Gold's GymGold's Gym has been the world's trusted fitness authority since 1965. From its beginning as a small gym inVenice,California, Gold's Gym has grown into a global icon with nearly 700 locations in 29 countries. Featuring personalized transformation plans, state-of-the-art equipment, certified personal trainers, a diverse group exercise program and a supportive, motivating environment, Gold's Gym delivers the most dynamic fitness experience in the industry. The Gold's Gym experience includes GOLD'SSTUDIO which gives members access to boutique-style classes like GOLD'S FIT, GOLD'S BURN and GOLD'S CYCLE, all under one roof along with GOLD'S AMP, the first digital personal training app from a brick-and-mortar gym. More than a gym, Gold's Gym combines coaching, community and more than 50 years of fitness expertise to help people around the world achieve their potential through fitness. For more information, visitwww.goldsgym.comor follow Gold's Gym onFacebook,InstagramandTwitter.

Story continues

Original post:
Virtual Health Partners Teams Up With GOLD'S GYM To Instantly Give Millions Better Health On Demand - Yahoo Finance

Sleep paralysis is the feeling of being unable to move when you're falling asleep or waking up. That's because people experiencing sleep paralysis are awake and alert, but unable to move their muscles.

The condition is relatively common, says Gonzalo Laje, MD, director of Washington Behavioral Medicine Associates in Chevy Chase, Maryland. Roughly 8% of people in the U.S. will experience sleep paralysis at least once in their lives.

"The body paralyzes itself during REM sleep, so we don't act out our dreams and hurt ourselves or our bedpartners," says Nate Watson, MD, co-director of the University of Washington Medicine Sleep Center.

Advertisement

Sleep paralysis can occur at two points, says Patricia Celan, MD, a psychiatry resident at Dalhousie University in Nova Scotia, Canada.

However, many people with sleep paralysis develop anxiety because the episodes can be frightening. In some cases, this can even cause insomnia if people feel afraid to sleep, Laje says. If that happens or if episodes become more frequent, it's time to seek professional help.

"There is no definitive cure for sleep paralysis, but if someone is bothered by it, there are actions that can be taken to reduce its risk of occurring," Celen says.

In fact, people who say they have good sleep quality are less likely than those who have bad sleep quality to experience sleep paralysis.

"Treating sleep paralysis involves optimizing sleep habits," Celen says. "That means improving sleep hygiene so you can fall asleep more easily and get a full night's rest."

If that's the case, it's most important to treat those conditions, like sleep apnea or depression, as it can help prevent sleep paralysis and improve your overall health.

Knowing more about sleep paralysis like the fact that it's common and not actually harmful can make occurrences easier to deal with and help reduce anxiety about the condition.

Some types of CBT like CBT-I, which is used to treat insomnia also teach relaxation techniques that are useful for improving your sleep hygiene and getting better sleep.

There is some early research that selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, can help treat sleep paralysis.

If you experience sleep paralysis once, it's not an immediate cause for concern, but you should focus on improving your quality of sleep.

"Although scary when it occurs, sleep paralysis is generally brief, self-limited, and does not indicate the presence of narcolepsy," Watson says. "When it occurs, it is a sign that your sleep may not be healthy."

Read the rest here:
What causes sleep paralysis and how to reduce your risk - Business Insider India

Many veterinarians will agree that preventive care is the secret to keeping pets healthy and happy at all times.However, achieving this can prove to be a daunting task especially when your clients do not believe it to be true.It is for this reason that most veterinarians are looking forward to helping clients understand the significance of preventative healthcare and the value of making visits to the veterinarian.One professional who is already raising the bar of quality and service in veterinary medicine is Miamis Dr. Xavier Meaux.

Born and raised in Puerto Rico, Dr. Xavier Meaux has greatly transformed the veterinary industry.After receiving his Bachelors in Animal Science from Purdue University in 2002, he went on to graduate from Tuskegee University School of Veterinary Medicine in 2006.It is after his graduation that he started his quest of making the veterinary industry better.

After amassing years of experienceas a relief emergency veterinarian, Dr. Meaux together with Pedro Armstrong, DVM, DACVIM, decided to start a company called Mobile Pet Imaging.This is after witnessing how patients with neck discomfort find it hard to eat, yet most radiologists and doctors would think twice before putting the patient in a CT scanner.

Mobile Pet Imaging is already changing the veterinary landscape by making imaging technology more accessible to patients having neck discomfort and others with less daunting features such as floppy ears.What is even more fascinating is the fact that the company delivers robotic high-definition CT (HD CT), fluoroscopy, and IR straight to the doorsteps of veterinary facilities. For Dr. Meaux, this is just but a new beginning for veterinarians with many things expected in the future.

Originally posted here:
On the road with Dr. Xavier Meaux - Jill Lopez

Verdict Medical Devices caught up with Vectorious medical director Dr Leor Perl to learn more about the V-LAP system. Credit: Vectorious The V-LAP is a miniature device of 2.5 millimetres in diameter which anchors to the interatrial septum. Credit: Vectorious Data from V-LAP is transmitted out into an external belt, which sends the information to the cloud. Credit: Vectorious

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Many people, both healthy and sick, use wearable devices to monitor their body and track their health. Its common knowledge that the readings from these devices wont be the most accurate in the world, but under the right circumstances they can provide interesting titbits about how a person is doing physically. But when it comes to monitoring serious health conditions, patients need something more heavy-duty.

Around 26 million people worldwide live with heart failure, where the muscles of the heart struggle to pump blood around the body. All people with chronic heart failure will need monitoring, but it can be hard to predict when adverse events arising from the condition will occur until theyre already happening.

Enter Vectorious. The Israeli medtech company has developed the worlds first in-heart computerised device, the V-LAP. V-LAP is a miniature, wireless, battery-free microcomputer that rests directly on the hearts interatrial septum and provides precise pressure readings to patients and clinicians at the push of a button.

The data is passed through an accompanying portable belt, which wirelessly syncs with the implant and then transmits information from the device securely into the cloud. Using artificial intelligence (AI), clinicians can see a preventative analysis of any heart anomalies, detecting potential risks before they occur and helping to prevent them.

Verdict Medical Devices caught up with Vectorious medical director Dr Leor Perl to learn more about the implantable blood pressure monitor.

Chloe Kent: How does the V-LAP device work?

Leor Perl: The V-LAP is silent and does not work throughout the day unless it is being activated by an external unit. The external unit does two main things one, it transmits energy by inductive coupling to the implant, creating a situation where the implant begins measuring pressure. It can give you information on the heart rate, temperature, pressure rating. It holds a lot of information because its a high-fidelity, high-resolution waveform each beat.

The implant has a computer within it, theres an AC chip, and it corrects for drift, which is a major issue with biological tissues in general. The data is then transmitted out into the external belt, which sends the information to the cloud. Clinicians can then get a pressure reading remotely, with heart rate and the temperature and so on, anywhere in the world.

CK: What is this experience like for a patient?

LP: Its a tremendous change. The patient does have to undergo the implantation procedure. It takes minutes; its a minimally invasive procedure. We get some local anaesthesia and we go through the femoral vein via a needle into the heart and implant it there. Its a miniature device, its 2.5 millimetres in diameter, and its anchored to the interatrial septum, so it just sits there like any other device thats being implanted in the heart.

Assuming the patient is compliant, measuring pressure once or twice a day, this data is transmitted to the team that takes care of these patients. Remember, these are patients with heart failure, who have a very high risk of being admitted to hospital once again. Heart failure is the number one condition in terms of the risk of readmissions. These are patients who come in and out of the hospitals, usually with severe symptoms of shortness of breath, they feel like they basically are being strangled to death. Its a very scary, uncomfortable, bad place to be at when they become admitted. This device from now on will foresee these acute exacerbations in heart failure where there is a risk for an acute heart failure event like that.

CK: Would you say your product represents a shift in how to approach patient care?

LP: Its a whole new world. Its a completely different way of treating these patients. Imagine trying to balance patients with diabetes without having glucose monitors. Treating patients with heart failure without having knowledge of the pressure within the cardiovascular system has been shown scientifically to be inaccurate. What they do presently is they measure weight, they look at symptoms and thats how medications have been titrated. Now we have objective, actionable data that shows us how to treat these patients.

CK: How do you feel the Covid-19 pandemic has impacted remote monitoring technologies like yours?

LP: Like many other crises in the past, humanity is going to grow. One of the things in the medical device world that I think people are appreciating now is that patients dont necessarily have to come into the hospital for some of the things that weve been doing. In fact, its probably better if they stay at home, with or without the pandemic. Thats been the case that weve been trying to make for years, because admissions in the US and the UK are very expensive, and it can actually be dangerous to come into the hospital when you have heart failure or other chronic diseases.

Theres been a change in the reimbursement strategies of many of the healthcare organisations to try and mitigate some of this flow into the hospital. Some physicians and some hospitals are looking at admissions actually, as a complementary event to the maintenance of care that we can perform at home.

CK: What do you see as the future of remote care post-pandemic?

LP: Things are not going to be what they used to be. The whole strategy of the hospital is going to change. In the world of telemonitoring, I think this is going to be the dawn of remote patient care. We have to realise that not all wearables and remote data is useful. To actually use data to care for these patients, physicians have to go through regulated medical devices that have been shown to pinpoint valuable information and we can treat these patients according to that data, which has been scientifically proven and legally regulated.

I think that 10 years from now, many chronic conditions, and maybe some acute ones, will be diagnosed, monitored and treated according to multiple sensors. Patients with chronic lung disease, cancer, chronic pain, neurological conditions these patients can benefit a lot from data that comes from remote monitoring. Thats going to be a huge shift because it requires infrastructure, it requires new training for the medical staff, but its going to make life easier and safer for patients.

CK: So youre seeing medicine shifting more towards prevention than cure?

LP: Im just going to throw in a crazy thought. Imagine a future where 20 years from now all babies born in the UK and Israel and the US are implanted with completely safe, durable and efficient sensors that can let you know when theyre at risk for things like sudden infant death syndrome, or when theyre having an allergic reaction or fever. And then as you become older, you go in during your puberty to get your puberty chip implanted and that lets you know when your cholesterol goes up, or if youre going into a risk category for diabetes. It sounds crazy, but I do think that our children will have that opportunity.

CK: I can see a lot of people being very averse to what youve suggested there how would you convince them its a good idea?

LP: Oh, yeah, therell be some pushback. It has to be regulated, has to be safe. But this is not to invade privacy and to know where you are, but to have information on disease to protect us.

Read more here:
Developing the world's first implantable blood pressure monitor - Medical Device Network

OSWEGO Public health touches all levels of the community; from pre-natal health care to hospice care, from the food we eat to the water we drink, from rabies control to emergency preparedness. With a variety of programs focused on these issues and more, the Oswego County Health Department strives to promote good health and wellness practices and ensure that communities throughout the county are thriving.

The county first established its public health nursing division in the 1960s, so it has a long tradition of delivering quality services to residents. Then, as now, its highly trained staff is on-call to provide skilled care on a variety of fronts, including preventative health care.

We are lucky to have these people on the front lines of the COVID-19 pandemic in our county, said Oswego County Legislature Chairman James Weatherup, District 9. Not all counties have staff with this level of training and expertise in epidemiology. They work tirelessly every day to manage the countys response to the coronavirus while adhering to guidance set forth by the state.

Oswego County Legislator James Karasek, District 22, chairman of the Oswego County Health Committee agreed. Residents can be assured we have an excellent team responding to this crisis. Not only is our public health director a trained epidemiologist, but our nursing staff also has decades of combined experience in preventative health care.

Leading the team is Oswego County Public Health Director Jiancheng Huang. He arrived in Oswego County in 2012 after several years with the Maine Immunization Program of the Maine Centers for Disease Control (CDC); first as an epidemiologist, then as the programs director. A Harvard graduate with a degree in population and international health, Huang is experienced in biomedical research and has served various regional and national workgroups to promote the understanding of infectious disease and immunization.

Epidemiology is an important cornerstone of public health, said Huang. It is an evidence-based science that provides the foundation of our decision-making process. Only with thorough investigation and unbiased analysis can we identify cause and effect, and then determine the best course of action that is, the most effective and appropriate responses to public health issues.

It is these very life-saving practices that brought him into the field of public health.

I realized that as a doctor, I could only treat patients one by one, said Huang. But as a member of a public health agency, we can address many of the broader issues that impact the well-being of our residents and effect real change. In this way, the whole of the population is the patient and we can help educate and encourage people to improve the overall health of the community. This is what epidemiology is.

Choosing to work in a rural location is no accident either. Through his internship in a rural hospital, he recognized the need for quality public health practices in that setting and knew he could be the most help there.

While Huang has largely worked with rural populations, he nevertheless has had experience with major public health crises before this, including severe acute respiratory syndrome (SARS) and H1N1.

I worked with the SARS outbreak in 2003 and the H1N1 pandemic in 2009, said Huang. COVID-19 is perhaps the most challenging of the three in its effect on public health. None of the past outbreaks were at a scale that is close to this.

That being said, he continued. I have complete faith in the capabilities of our epidemiology team and in the skills and experience of our entire staff. Public health relies on teamwork. With the dedication of our health department team and the support of our community, I know that we will all get through this difficult time together.

Over the years, Oswego County has made a significant investment in its staff to increase their epidemiology capabilities.

Tina Bourgeois is a senior LPN with 30 years of experience focused on investigating communicable diseases and promoting immunizations.

COVID-19 hasnt really changed what I do most days, said Bourgeois. Every year, I investigate hundreds of reportable communicable diseases through contact tracing. The thing thats new is the virus itself, so were learning more about that every day.

When a patient tests positive for coronavirus, Bourgeois contacts that person to go over the results. She said that can be difficult because there is a lot of fear, confusion and uncertainty about this new virus.

Many people are scared, they dont know what to expect, she said. As an investigator you have to be kind. Listen to their concerns and give them some reassurance. Be honest and answer all their questions as best as you can. When I talk to people, I make sure they understand their diagnosis and are receiving the proper treatment so they can get well.

Investigators also ask if patients have been in contact with other people so they can determine if others may have been exposed or need treatment. We have to reduce the spread of this disease, so its not uncommon for me to have to tell people they need to stay home for a period of time, said Bourgeois. Well review work restrictions or talk about how to prevent exposing other family members in the home to the disease.

Huang said, Tinas experience is one of the strengths of this team. She asks so many good, detailed questions. We learn a lot from her about contact tracing.

Oswego County has long encouraged the use of educational and career incentives where possible to better develop an employees capabilities.

Chantel Eckert, DNP, RN, has repeatedly taken on the challenge of higher education to the benefit of the countys health department. She said, Advanced education has provided me with a solid foundation in clinical prevention and population health which has been instrumental in helping me see the big picture of this pandemic.

Eckert serves as program manager for Healthy Families Oswego County and, as a supervising public health nurse, continues to assist with coverage of the health departments nursing division. In the wake of the current pandemic, this includes helping with the nursing phone bank by answering medical questions and concerns from the public. She also exercises her analytical skills to track the virus activity.

The majority of my time is spent collecting and analyzing data related to the coronavirus, said Eckert. Using a systematic approach, I can identify trends with the virus and provide accurate and timely information to our team. This helps them with public reporting, contact investigations and, most importantly, determining the appropriate prevention and control measures to implement to reduce the spread of the disease.

Huang said, This is the science of epidemiology. It is how we respond to the pandemic and keep our residents safe. Scholarly data analysis is a critical skill during a public health crisis. Chantels doctoral education is a valuable asset to the team.

Jodi Martin, RN, BSN, continues along the path of higher learning to further enhance her skills and capabilities with the health department. She completed a Health Leadership Fellow

Program last year and is now pursuing her masters degree in nursing with an emphasis on public health.

My fellowship and current studies, combined with a decade-long career in public health have helped prepare me for this challenge, said Martin. I view the data in a new way which gives me a better understanding of public health activities and improves my ability to respond to this unprecedented crisis.

Martin, also a supervisory public health nurse, works with many public health programs in the departments preventative care unit, including communicable disease surveillance and the immunization program.

Last summer, Oswego County saw a spike in hepatitis A cases, the highest in the state. Im very proud of our work in identifying the high-risk populations and finding creative ways to reach out to them, she said. We were able to complete difficult contact investigations and provide vaccinations to at-risk individuals.

Huang added, Our team was very successful in containing this disease and received praise from the state Department of Health for our hard work. In addition, several other counties in the state asked us to share our disease containment activities. Jodis creative thinking was an integral part of that success. She continues to bring a fresh perspective on public health to the team.

Dr. Christina Liepke, medical director for Oswego County, brings nearly two decades of experience in family medicine to the team. A graduate of Upstate Medical University, Dr. Liepke served on the Oswego County Board for Health for several years before being named medical director for Oswego Countys Health Department and Hospice Program in 2014. She also maintains a family medicine practice with Port City Family Medicine.

The COVID-19 pandemic is a humbling experience; unprecedented in its magnitude, said Dr. Liepke. What I have learned from it is that we have an amazingly generous community and dedicated staff who are unwavering in their duties. Through it all, everyone on our health department team, from our nurses to the public health director, works day after day without complaint to safeguard our residents. It is a compassionate, collaborative and creative team qualities we need when facing such a unique disease and I am humbled and thankful to work with such amazing people.

Huang agreed, We have a wonderful team managing Oswego Countys response to the COVID-19 pandemic. Dr. Liepkes role is important to continue the countys long tradition of health care services and activities. Epidemiology is another branch of medicine and she brings great insights to our decision-making processes. Her input is indispensable to the entire team.

For more information about Oswego Countys COVID-19 response, go to oswegocounty.com or health.oswegocounty.com/covid-19. Additional questions can be directed to the Oswego County Health Department COVID-19 Hotline at 315-349-3330 from 8:30 a.m.-4 p.m. Monday through Friday. For information about emotional supports, visit the Oswego County Department of Social Services Division of Mental Hygiene at http://www.oswegocounty.com/mentalhygiene.

View original post here:
'Teamwork Makes the Dream Work' behind the front lines with the Oswego County Health Department - NNY360

Throughout the past week, Ohio Governor Mike DeWine was joined by Lt. Governor Jon Husted, and provided updates on Ohio's response to the COVID-19 pandemic, as well as state initiatives.

On Tuesday, Governor DeWine endorsed Wright-Patterson Air Force Base (WPAFB) and the surrounding Dayton region as the ideal location for the new United States Space Command headquarters.

"Wright-Patterson Air Force Base and the Dayton region would be excellent hosts for the U.S. Space Command's new headquarters," said Governor DeWine. "This area is already home to the National Air and Space Intelligence Center, Air Force Research Laboratory, Air Force Life Cycle Management Center, and Air Force Material Command. It's a powerful combination and a synergy that you can't find anywhere else."

In a letter sent to the Assistant Secretary of the Air Force, Governor DeWine endorsed the nomination submitted by Beavercreek Mayor Bob Stone. A letter signed by 22 area mayors and four county commission presidents was also submitted expressing mutual support for the Dayton region to be considered for the permanent U.S. Space Command headquarters.

The Department of the Air Force, in coordination with the Office of the Secretary of Defense, announced in May that it would accept nominations for the headquarters' location based on specific criteria. WPAFB and the Dayton region met all of the screening requirements.

If selected, the new headquarters could bring up to 1,400 personnel to Ohio.

Copies of the letters sent can be found at governor.ohio.gov.

Also on Tuesday, Governor DeWine announced two public awareness campaigns aimed at spreading awareness of COVID-19 prevention measures that impact the well-being of Ohioans and the Ohio economy.

The messages of these ads are clear, said Governor DeWine. Ohioans, by continuing to practice good prevention, can do two things at once, help stop the spread of COVID-19, and responsibly and safely get back to work.

The first campaign, called I Believe, focuses on real Ohioans and the prevention measures they take to prevent the spread of COVID-19. These 15-second ads, provided by the Ohio Department of Health, will air for three weeks on broadcast, cable, and social media across the state. The PSAs feature two Ohio healthcare professionals.

I Believe (1)

Dr. Kevin Sharrett, MD, is a primary care physician with Cedarville and Jamestown Family Practice. He is the Medical Director for the Greene County Health Department and the Medical Director for Rural Health for the Kettering Health Network. He has served as the Greene County Coroner since 1997. A graduate of Wright State University School of Medicine, Dr. Sharrett also is a farmer and has dedicated his career to serving rural Ohioans.

I Believe (2)

Shareece Mashiska, RN, has been caring for patients in the Youngstown/Warren communities for more than 15 years. A nurse manager at Mercy Health St. Elizabeth Youngstown Hospital, Shareece began her career in the intermediate unit at Mercy Health St. Joseph Warren Hospital before becoming an intensive care nurse working both in-patient and on Mercy Healths mobile intensive care unit. Currently residing in the Mahoning Valley, Shareece believes social distancing remains a critical piece of keeping our communities safe, which includes her own husband and three children.

Up to All of Us

The second campaign, called Up to All of Us, focuses on the importance of taking proper preventative precautions, such as maintaining social distance and washing hands, to get Ohioans back to work and Ohio's economy working again. The ad, provided by the Ohio Bureau of Workers Compensation, will air for three weeks on broadcast and cable television and features an emergency room physician and a local restaurant owner and operator.

Laura Espy-Bell, MD, MHA, FACEP is a board-certified Emergency physician and a native of Columbus, Ohio. She is a graduate of Spelman College in Atlanta, GA where she received her Bachelor of Arts in Economics in 2003. Dr. Espy-Bell received her Master of Healthcare Administration (MHA) from the University of North Carolina at Chapel Hill in 2005. Dr. Espy-Bell graduated from The Ohio State University College of Medicine in 2011. Dr. Espy-Bell has been an active member of the OhioHealth medical staff for the past 6 years as an Emergency Medicine attending physician with Mid-Ohio Emergency Services (MOES) and has provided quality health care in several OhioHealth emergency departments.

Gary Callicoat is the president of Rusty Bucket Restaurant and Tavern, which he first opened in 2002. Reflecting a long record of giving back to the hospitality industry, Callicoat serves on the board of the Ohio Restaurant Association (ORA) and is equally committed to supporting charitable causes of the communities in which he does business. He is also on the board of the ORAs Education Foundation.

FIREWORKS

Lt. Governor Husted noted that Independence Day fireworks shows can proceed, but large gatherings are still prohibited at this time. He encouraged any community that plans on holding a fireworks event to do so safely. Spectators are encouraged to find ways to celebrate the Fourth of July in small groups, such as by watching displays from their porches, backyards, or cars.

CRIMINAL JUSTICE GRANTS

Governor DeWine announced the first round of funding being distributed to local criminal justice entities as part of the Coronavirus Emergency Supplemental Funding Grant.

Approximately $2.1 million will be awarded to a total of 65 local criminal justice agencies including law enforcement, probation/parole offices, corrections agencies, courts, and victim service providers.

The funding can be used toward COVID-19 expenses such as cleaning supplies, PPE, and medical supplies like thermometers. The funding will also be used to pay for technology upgrades that are needed for teleworking or other virtual services.

A complete list of grant recipients can be found at coronavirus.ohio.gov.

A total of nearly $16 million was awarded to Ohio's Office of Criminal Justice Services (OCJS) for this program as part of the CARES Act. OCJS continues to process other grant applications theyve already received and are still accepting new applications from agencies that have not yet requested funding.

More information on how to apply can be found at http://www.ocjs.ohio.gov.

On Wednesday, Governor DeWine, First Lady Fran DeWine, and Lt. Governor Husted visited Lordstown Motors for a first look at the 2020 Endurance All-Electric Pickup Truck.

On Thursday, Governor DeWine invited President and CEO of UC Health Richard P. Lofgren, MD, MPH, FACP to give an update on the status of COVID-19 in Hamilton County and the surrounding areas.

The effective reproductive ratio, also known as R naught, measures how many people will be infected by a sick individual. The R naught had reached 2.4 in that region in April. In recent weeks, the R naught had declined to below one. However, in the last 10 days, the R naught has doubled over the last 10 days in the Cincinnati region.

Dr. Lofgren explained that the increase in cases is not only due to the tests being performed, but the increase shows there is a greater presence of the COVID-19 in the area, and it is spreading in the community. He said it serves as a reminder about the importance of wearing a mask in public, washing your hands, sanitizing frequently touched surfaces, and keeping social distance.

OHIO 2-1-1

Governor DeWine announced that the Ohio Department of Health will continue funding for the valuable 2-1-1 service as Ohio enters into the next phase of the COVID-19 pandemic.

2-1-1 is a phone service that connects thousands of Ohioans to local non-profit and government services for healthcare, food and meals, housing, transportation, mental health, and legal services.

At the beginning of the year, the service was available in 51 of Ohios 88 counties. When the pandemic began, Ohio EMA asked Ohio AIRS, the non-profit that governs Ohio 2-1-1, to provide service to the remaining 37 counties in Ohio, which happened in March.

Ohioans can also dial 877-721-8476 to get connected to 2-1-1.

Also on Thursday, Governor DeWine made several appointments to various boards and commissions, as well as two judicial appointments.

CURRENT OHIO DATA

As of Friday afternoon, there are 48,638 confirmed and probable cases of COVID-19 in Ohio and 2,788 confirmed and probable COVID-19 deaths. A total of 7,570 people have been hospitalized, including 1,904 admissions to intensive care units. In-depth data can be accessed by visiting coronavirus.ohio.gov.

For more information on Ohio's response to COVID-19, visit coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

Read the original post:
Pandemic Response Week In Review - Vermilion Ohio - discoververmilion.org

Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene therapy study.

We are excited to share updated data from our combined haemophilia A programme at this years virtual ISTH 2020, said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. These data exemplify our efforts to increase our knowledge and capabilities in haemophilia A, including in the context of gene therapy, with the goal of advancing care and providing innovative treatment approaches for people living with this chronic condition.

SPK-8011 data presentationData from the initial dose cohorts of Sparks phase I/II SPK-8011 gene therapy study in haemophilia A will be presented at the congress. Updated data from five participants in the initial dose cohorts, who are up to 142 weeks post-vector infusion, show stable and durable factor VIII expression and a 91% reduction in annualised bleed rate (ABR). There is no evidence of decline in factor VIII expression after more than two years of follow up.1

These data indicate an acceptable safety profile, with no development of factor VIII inhibitors. Furthermore, they represent the longest stable expression of factor VIII following gene transfer and support the use of adeno-associated virus-mediated (AAV-mediated), liver directed gene therapy to achieve durable factor VIII expression for the treatment of haemophilia A.1

Key Hemlibra data presentationsData for Hemlibra will be featured in four poster presentations at the congress. This further supports the comprehensive body of clinical evidence available for Hemlibra, including from the HAVEN studies the most extensive clinical development programme in haemophilia A. This includes results from the second interim analysis of the phase IIIb STASEY study, evaluating the safety and tolerability of Hemlibra prophylaxis in people with haemophilia A with factor VIII inhibitors.

Further data from the STASEY study to be presented outline surgical experiences in the trial, as well as additional insights into the pharmacokinetics and pharmacodynamics profile of Hemlibra.

Roche will also share the first clinical data from the phase III HAVEN 5 study, evaluating the efficacy, safety and pharmacokinetics of Hemlibra in 70 people with haemophilia A with and without factor VIII inhibitors in the Asia-Pacific region. The study met its primary endpoint, demonstrating that Hemlibra prophylaxis dosed every week or every four weeks resulted in a statistically significant 96% (p<0.0001) reduction in the number of treated bleeds over time compared to those receiving no prophylaxis.5 In addition, all secondary bleed-related endpoints were met with clinically meaningful results. Overall, this study showed that Hemlibra was effective and well tolerated in this population.5 HAVEN 5 was conducted as part of the post-approval agreement with the Chinese health authorities to provide supportive data in people with haemophilia A in China, and was expanded to enrol patients from other Asia-Pacific countries.

Key data presentations on impact of haemophilia ARoche will also present two analyses providing insights into clinical outcomes from the CHESS II (Cost of Haemophilia in Europe: a Socioeconomic Survey-II) study evaluating disease burden in people with haemophilia A. The first analysis examines clinical outcomes in adults with mild, moderate and severe haemophilia A without factor VIII inhibitors, focusing on bleeding episodes and joint outcomes. Results show most people with mild and moderate haemophilia A (91% and 98% respectively) did not receive prophylaxis and the majority of these experienced one or more bleeds (74% and 85% respectively).6 These data demonstrate the potential treatment needs in these populations, and the clinical burden on those living with mild and moderate haemophilia A. Additional data from the CHESS II study explores the correlation between bleed frequency and physical activity levels in the same patient population, suggesting there is a correlation between the two.7

Key abstracts from Roche and Spark that will be presented at ISTH can be found in the table below.

Follow Roche and Spark on Twitter via @Roche and @Spark_tx respectively, and keep up to date with ISTH 2020 Congress news and updates by using the hashtag #ISTH2020.

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Monday 13 July 2020, 10:39 - 10:51 EST

Virtual Meeting Room 2

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 11:03 - 11:15 EST

Virtual Meeting Room 3

Second of three presentations occurring in the session, State of the Art Session on Hemophilia and Rare Bleeding Disorders on Sunday 12 July 2020, 8:45 10:00am EST

About Hemlibra (emicizumab)Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins involved in the natural coagulation cascade, and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks (after an initial once weekly dose for the first four weeks). Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh), with kxwh as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the US Food and Drug Administration.

About haemophilia AHaemophilia A is an inherited, serious disorder in which a persons blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 320,000 people worldwide,8,9 approximately 50-60% of whom have a severe form of the disorder.10 People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their disorder, people with haemophilia A can bleed frequently, especially into their joints or muscles.8 These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage.11 A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies.12 Inhibitors are antibodies developed by the bodys immune system that bind to and block the efficacy of replacement factor VIII,13 making it difficult, if not impossible to obtain a level of factor VIII sufficient to control bleeding.

About Roche in haematologyRoche has been developing medicines for people with malignant and non-malignant blood diseases for over 20 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera/Rituxan (rituximab), Gazyva/Gazyvaro (obinutuzumab), Polivy (polatuzumab vedotin), Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, and Hemlibra (emicizumab). Our pipeline of investigational haematology medicines includes idasanutlin, a small molecule which inhibits the interaction of MDM2 with p53; T-cell engaging bispecific antibodies, glofitamab and mosunetuzumab, targeting both CD20 and CD3; Tecentriq (atezolizumab), a monoclonal antibody designed to bind with PD-L1; and crovalimab, an anti-C5 antibody engineered to optimise complement inhibition. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.About Roche and Spark Therapeutics gene therapy research in haemophilia AWe believe gene therapy has the potential to revolutionise medicine and improve the lives of patients with genetic and other serious diseases. Pairing Roches long-standing commitment to developing medicines in haemophilia with Spark Therapeutics proven gene therapy expertise brings together the best team of collaborators researching gene therapies in haemophilia A.

It is our aligned objective to develop gene therapies for haemophilia A that, with the lowest effective dose and the optimal immunomodulatory regimen, demonstrate safety, predictability, efficacy, and durability for patients.

About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References[1] George L et al. Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A. [oral presentation no. OC03.5] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[2] Jimenez-Yuste V et al. Second Interim Analysis Results from STASEY Trial: A Single-arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluates the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII inhibitors. [poster no. 0958] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[3] Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. NEJM 2017; 377:809-818.[4] Young G et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood 2018; 132 (Supplement 1): 632.[5] Wang S et al. A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Persons with Hemophilia A in the Asia-Pacific region (HAVEN 5). [poster no. 0957] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[6] Nissen F et al. An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study [oral presentation no.OC 09.3] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[7] Nissen F et al. Associations Between Physical Activity Levels and Bleeding Frequency in People with Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study. [poster no. 0943] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[8] WFH. Guidelines for the management of haemophilia. 2012 [Internet; cited 2019 July]. Available from: http://www1.wfh.org/publications/files/pdf-1472.pdf.%5B9%5D Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet 2012; 370:1447-1456.[10] Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.[11] Franchini M, Mannucci PM. Haemophilia A in the third millennium. Blood Rev 2013; 179-84.[12] Gomez K, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014; 12:s319-s329.[13] Whelan, SF, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of haemophilia A patients. Blood 2013; 121:1039-48.

Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com- Nicolas Dunant (Head)- Patrick Barth- Daniel Grotzky- Karsten Kleine- Nathalie Meetz- Barbara von Schnurbein

Go here to read the rest:
Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A - GlobeNewswire

RAWLINS The MHCC Family Practice Clinic would like to introduce their newest provider, Dr. Gary Mikesell, D.O.

Born and raised in Rawlins, Mikesell began his medical career in 1982 with Memorial Hospital of Carbon County where he worked as a patient transporter. After graduating from Rawlins High School, he attended the University of Wyoming for a year before completing a two year mission with Church of Jesus Christ of Latter-Day Saints. Mikesell then returned to the University of Wyoming where he majored in Microbiology. After transferring to Brigham Young University, he graduated with a degree in Microbiology and Pre-Med. He was then accepted to medical school at Western University/College of Osteopathic Medicine of the Pacific in southern California. Dr. Mikesell completed medical school in 1996.

Dr. Mikesell has built his career on family practice and urgent care, with over 21 years experience in both. In addition, he also has a strong interest in preventative medicine and sports medicine. He is trained to do spinal and musculoskeletal manipulations to help with back, neck and musculoskeletal pain. Dr. Mikesell also has a Buprenorphine Waiver which allows him to treat patients with narcotic addictions.

Dr. Mikesell enjoys hunting, fishing, camping and taking vacations with his wife, Leticia, and four children. He is very involved in the church and has a strong faith in God. Starting today, Dr. Mikesell will begin seeing patients at the MHCC Family Practice Clinic. Contact the clinic at 307-324-8494 to schedule an appointment.

Here is the original post:
Rawlins native returns home to practice medicine | Hospitality & Tourism - Wyoming Business Report

Nearly 35,000 Children in the Asia Pacific Receive Eye Exams with Myopia Screening

Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, has announced new clinical research on Myopia progression in children and detailed significant child Myopia screening and education progress in the Asia Pacific region. The clinical research and public health programs are part of the comprehensive Myopia research collaboration with the Singapore Eye Research Institute (SERI) and Singapore National Eye Centre (SNEC) launched in April 2019.

Current estimates show that by 2050 half of the worlds population is expected to be myopic, with a disproportionate impact on our children, said Xiao-Yu Song, MD, PhD, Global Head of Research and Development, Johnson & Johnson Vision Care, Inc. Through close collaborations with SERI, SNEC, and other aligned public health groups, we are helping to address this crisis by building a better understanding of the science and biology behind Myopia and developing comprehensive programs to address and treat the disease.

Researchers for the collaboration presented some of its first clinical research findings at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The collaborations five studies at ARVO focus on new techniques and practices to better predict Myopia progression and vision impairment, significant challenges for eye care professionals when so much of Myopia disease progression is still to be understood.

The research team presented new findings on Myopia progression from one of the largest clinical research studies with children. In the study of 674 myopic children aged seven to 10-years old over two-years, the authors found that a childs prior year Myopia progression correlates with immediate subsequent year progression. That is, the investigators found that children with slow Myopia progression during the first year generally had slow progression in year two, while children with fast Myopia progression in year one generally had fast progression in year two.

However, the authors report that year-over-year progression as a single factor does not fully predict long-term Myopia progression and that a childs age and parental Myopia are important additional variables to consider in choosing whether to treat a childs progression.

Globally, for parents of children with Myopia, and eye care professionals, an important takeaway is the need for myopic patients to receive regular annual check-ups, said study lead author Noel Brennan, PhD, Global Lead, Myopia Control, Johnson & Johnson Vision. While Myopia progression rates will naturally be followed from year-to-year, it is also important that eye care professionals consider the age of Myopia onset and parental Myopia.

The author presentation and study, Annual Myopia Progression and Subsequent Year Progression in Singaporean Children, is published on ARVOLearn as part of ARVOs virtual congress.

MYOPIA SCREENING AND EDUCATION PROGRAM PROGRESS IN ASIA PACIFIC

Since the formal launch of the collaboration just over a year ago, Johnson & Johnson Vision, Johnson & Johnson Global Community Impact, SERI, and SNEC have also been working to advance critical Myopia screening and education programs in the Asia Pacific region where current prevalence rates among young people are as high as 80 to 97 percent in urban areas in East Asia and Singapore.

In China, among children ages six to 18, Myopia prevalence rises from less than 10 to 80 percent. In Singapore, one in two children develop Myopia by the age of 12, and 75 percent of teenagers are myopic and rely on glasses.Left unchecked, in some patients, Myopia can lead to blindness or other eye health conditions that can severely impact vision and overall well-being.

Tackling the Myopia epidemic globally requires a comprehensive approach that includes critical education and screening campaigns, said Dr. Song. We are very pleased by the progress of the public health programs in Asia being supported by the collaboration, and that young children are receiving comprehensive eye exams and necessary referrals when diagnosed with Myopia. We look forward to continued progress as we learn to manage these initiatives through the COVID-19 pandemic.

Working through the Fred Hollows Foundation, and Chinas Yunnan Provincial Health Commission and Provincial Education Department, the collaboration launched its three-and-a-half-year Child Eye-Health Program in Chinas Yunnan Province in August 2019. The program trains ophthalmologists, refractionists, community health workers, and teachers in screening techniques and supports student screening programs. In the second half of 2019, the collaboration has already supported the screening of nearly 30,000 primary school students in Yunnan Province, and provided eye health and myopia prevention knowledge to almost 20,000 students.

The collaboration has also become a strategic partner with the Ministry of Educations Research Center for Prevention, Control and Diagnosis of Myopia to support the improvement of Myopia public awareness and the development of Myopia awareness education tools. In addition, the collaboration is working with the Beijing Preventative Medicine Association and Beijing CDC on a Myopia school screening program that is seeking to examine 4,000 students from September 2019 to the end of 2020.

Read more:
J&J presents Significant Progress in Myopia Screening and Education in APAC - BSA bureau

A research report on the Medical Wellness market has been presented by Market Expertz, offering an extensive analysis of the Global Medical Wellness Market where the readers can benefit from the complete market study with all the relevant information about the market.

This is the latest report covering the current COVID-19 scenario. The coronavirus pandemic has greatly affected every aspect of life worldwide. This has brought along various changes in market conditions.

The rapidly changing market scenario and the initial and future assessment of the impact are covered in the research report. The report discusses all the major aspects of the market with expert opinions on the current status along with historical data.

Get a Free Sample Copy of the Medical Wellness Market Report with the Latest Industry [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/45479

Leading Medical Wellness manufacturers/companies operating at both regional and global levels:

Massage EnvySteiner Leisure LimitedWorld GymFitness WorldUniversal CompaniesBeauty FarmVLCC Wellness CenterNanjing ZhaohuiEdge Systems LLCHEALING HOTELS OF THE WORLDGolds Gym International

This report consists of reliable data on the investment opportunities, market dynamics, competition analysis, major market players, basic industry facts, important figures, prices, sales, revenues, gross margins, market shares, key business strategies, top regions, among others.

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/45479

Global Medical Wellness Market Segmentation

This market has been segmented into Types, Applications, and Regions. The growth calculation of each segment provides an accurate forecast of the sales in terms of volume and revenue for the period 2016-2027. This study can help readers expand their business by targeting qualified niche markets. Market share data is also available on the regional and global levels.

In market segmentation by types of Medical Wellness, the report covers-

Complementary and Alternative MedicineBeauty Care and Anti-AgingPreventative & Personalized Medicine and Public HealthHealthy Eating, Nutrition & Weight LossRejuvenationOther

In market segmentation by applications of the Medical Wellness, the report covers the following uses-

FranchiseCompany Owned Outlets

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Medical Wellness sector and can help companies in deciphering the optimum business move to reach their desired business goals.

To Obtain All-Inclusive Information and Accurate Forecast of the Medical Wellness Market, Request a Custom [emailprotected] https://www.marketexpertz.com/customization-form/45479

Global Medical Wellness Market Regions Level Analysis:

Geographically, regions covered in the research report are North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The analysts provide competitive analysis for each region and competitor separately.

Regional analysis is a major part of this report. It focuses on the sales of the Medical Wellness on the regional level. The data provides the readers with a detailed and extensive country-wise volume analysis and region-wise market size analysis of the global Medical Wellness market.

It offers an in-depth assessment of the growth aspects of the market in the key countries. The competitive landscape chapter of the global Medical Wellness market report delivers key information regarding the market players including the company overview, company profiles, total revenue, market potential, growth prospects, global presence, sales and revenue, market share, production sites and facilities, product offerings, latest developments and innovations and key strategies adopted.

Key Coverage:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast by Types6. Global Market Analysis and Forecast by Applications7. Global Market Analysis and Forecast by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/medical-wellness-market

To summarize, the global Medical Wellness market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

Read the original here:
Medical Wellness Market Demand (2020-2027) | Covering Products, Financial Information, Developments, SWOT Analysis And Strategies | Market Expertz -...

Can people spread the coronavirus if they don't have symptoms? 5 questions answered about asymptomatic COVID-19 Screening for symptoms can catch some cases of COVID-19, but about people who are infected but not showing any symptoms? AP Photo/John Raoux Monica Gandhi, University of California, San Francisco

Screening for symptoms of COVID-19 and self-quarantine are good at preventing sick people from spreading the coronavirus. But more and more evidence is suggesting that people without symptoms are spreading the virus too. Monica Gandhi, an infectious diseases physician and researcher at the University of California, San Francisco, explains what is known about asymptomatic spread and why she thinks it may be a big part of what is driving the pandemic.

SARS-CoV-2 the virus that causes COVID-19 can produce a range of clinical manifestations.

Some people who are infected never develop any symptoms at all. These patients are considered true asymptomatic cases.

When people do get sick from the coronavirus, it takes on average five days and as many as two weeks to develop symptoms that can range from very mild to extremely dangerous. The time between initial infection and the first symptoms is called the pre-symptomatic phase.

As an infectious disease physician, when I hear about asymptomatic spread of SARS-CoV-2, I think of a person who doesnt have symptoms at the moment they give the virus to someone else. It doesnt matter whether they are a true asymptomatic case or just pre-symptomatic; the public health risk is the same.

Estimates of the proportion of true asymptomatic cases those who are infected and never develop symptoms range from 18% to over 80%. The reasons for the huge range in estimates are still unclear, but some studies are better than others.

The most accurate way to determine the rate of asymptomatic cases is to test people regardless of whether or not they have symptoms an approach called universal mass testing and track them over time to see if they develop symptoms later. A recent mass testing campaign in San Francisco found that 53% of infected patients were asymptomatic when first tested and 42% stayed asymptomatic over the next two weeks.

Another recent paper compared the evidence from 16 studies and estimated the overall rate of asymptomatic infection to be 40%-45%. This is in line with the San Francisco finding, but the studies sampled were of various quality and size and likely include some pre-symptomatic cases.

Though none of these studies is perfect, a lot of evidence supports a true asymptomatic rate of around 40%, plus some addition fraction of patients who are pre-symptomatic.

Compared to most other viral infections, SARS-CoV-2 produces an unusually high level of viral particles in the upper respiratory tract specifically the nose and mouth. When those viral particles escape into the environment, that is called viral shedding.

Researchers have found that pre-symptomatic people shed the virus at an extremely high rate, similar to the seasonal flu. But people with the flu dont normally shed virus until they have symptoms.

The location of the shedding is also important. SARS-CoV the virus that caused the SARS epidemic in 2003 does not shed very much from the nose and mouth. It replicates deep in the lungs. Since SARS-CoV-2 is present in high numbers in a persons nose and mouth, it is that much easier for the virus to escape into the environment.

When people cough or talk, they spray droplets of saliva and mucus into the air. Since SARS-CoV-2 sheds so heavily in the nose and mouth, these droplets are likely how people without symptoms are spreading the virus.

Public health experts dont know exactly how much spread is caused by asymptomatic or pre-symptomatic patients. But there are some telling hints that it is a major driver of this pandemic.

An early modeling estimate suggested that 80% of infections could be attributed to spread from undocumented cases. Presumably the undocumented patients were asymptomatic or had only extremely mild symptoms. Though interesting, the researchers made a lot of assumptions in that model so it is hard to judge the accuracy of that prediction.

A study looking at outbreaks in Ningbo, China, found that people without symptoms spread the virus as easily as those with symptoms. If half of all infected people are without symptoms at any point in time, and those people can transmit SARS-CoV-2 as easily as symptomatic patients, it is safe to assume a huge percentage of spread comes from people without symptoms.

Even without knowing the exact numbers, the Centers for Disease Control and Prevention believes that transmission from people without symptoms is a major contributor to the rapid spread of SARS-CoV-2 around the world.

Any time a virus can be spread by people without symptoms, you have to turn to preventative measures.

Social distancing measures and lockdowns work, but have large economic and social repercussions. These were necessary when epidemiologists didnt know how the virus was spreading, but now we know it sheds at high quantities from the upper respiratory tract.

This means that universal mask wearing is best tool to limit transmission, and there is evidence to back that idea up.

On April 3, the CDC recommended that all members of the public wear facial coverings when outside of the house and around others. The World Health Organization finally followed suit and recommended universal public masking on June 5.

At this point, no one knows exactly how many cases of COVID-19 are from asymptomatic spread. But I and many other infectious diseases researchers are convinced that it is playing a major role in this pandemic. Wearing a mask and practicing social distancing can prevent asymptomatic spread and help reduce the harm from this dangerous virus until we get a vaccine.

[You need to understand the coronavirus pandemic, and we can help. Read The Conversations newsletter.]

Monica Gandhi, Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
Can people without symptoms spread COVID-19? Five questions answered about how the virus is spread | Opinion - pennlive.com

What is dexamethasone? Is it effective vs COVID-19?

MANILA, Philippines As the world struggles to find solutions to the novel coronavirus disease 2019 (COVID-19) pandemic, an occasional dose of hope comes to break the strain of dead ends.

Recently, the World Health Organization celebrated the steroid dexamethasone for its life-saving potential for critically ill COVID-19 patients.

The next challenge is to increase production and rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most. Demand has already surged, following the UK trial results showing dexamethasone's clear benefit. Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production, WHO Director-General Doctor Tedros Adhanom Ghebreyesus said in a Monday briefing.

This came after University of Oxford researchers found that dexamethasone reduces death in hospitalized patients with severe respiratory complications of COVID-19.

Here are your questions about dexamethasone, including its pros and cons, answered.

WHO: Dexamethasone is a corticosteroid used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects.

Dexamethasone was tested on hospitalized COVID-19 patients as part of the United Kingdoms national clinical trial RECOVERY (Randomised Evaluation of COVID-19 Therapy).

It was found to benefit critically ill patients in particular.

According to preliminary findings shared with WHO (and now available as a preprint), for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.

WHO took care to remind global stakeholders that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm.

The local Food and Drug Administration likewise warned against misuse or unsupervised chronic use of the drug, which they said could lead to serious adverse health reactions like:

If stopped abruptly, it may cause withdrawal symptoms such as hypotension, shockand coma.

Related: FDA warns public vs non-prescribed use of steroid dexamethasone

Similar to WHO, the Department of Health has warned the Filipino public against non-prescribed use of dexamethasone, reminding that no prophylaxis (preventive treatment) or cure exists yets for COVID-19.

We strongly urge the public not to rush to the drugstores, buy this drug, and take it without the supervision of a doctor, in order to be cured or be protected from the virus... It is highly important to note that though this may be considered as a breakthrough in science, the study on this drug as a cure for COVID-19 is yet to be peer-reviewed, Health Undersecretary Maria Rosario Vergeire said last week.

Dexamethasone is yet to undergo further trials and review, but we assure the public that the DOH is in coordination with the global medical community. The department remains in close collaboration with different experts both locally and internationally in the search for a cure and other treatments that are safe and effective against COVID-19.

Related: DOH: Steroid dexamethasone no 'magic pill' vs COVID-19

The FDA also issued an advisory reminding that the unauthorized sale of dexamethasone is strictly prohibited.

There are Dexamethasone products that are currently registered with the FDA. The drug should be only dispensed by licensed establishments to patients with valid prescription. The sale of unregistered Dexamethasone or sale of the drug without valid prescription or through online platforms is strictly prohibited.

See the original post:
What is dexamethasone? Is it effective vs COVID-19? - Philippine Star

Marco Bertorello via Getty Images

In March, as Vadim Gladyshev shifted through the reams of data detailing the kinds of people who were more likely to fall victim to Covid-19, the Harvard biochemist started to wonder if we were thinking about the viral infection in the wrong way.

In Europe, 95 per cent of those killed by the disease were aged 60 or over. According to the UN, the fatality rate for those over 80 is five times the global average. Although many infectious diseases impact older people disproportionately, with Covid-19 the skew towards older people is devastating. Given all this, Gladyshev wondered, why arent we treating Covid-19 as a disease of ageing?

As he watched the global arms race to try and find a treatment which either neutralised the SARS-CoV-2 virus or dampen the overactive immune response which leads to many of the deaths, Gladyshev one of the worlds leading experts on the causes of ageing could not help but ponder if academics and pharmaceutical companies across the world were heading down the wrong path. If Covid-19 has the greatest impact on the elderly, rather than targeting the virus, should we not be focusing more on strengthening the host? he says.

Since the 1930s, scientists have sought clues on how to turn back the ageing process in humans by first trying to extend lifespan in rodents, with two drugs rapamycin and metformin showing signs of promise. While it is doubtful that these drugs would be useful in severe cases of Covid-19 where patients are already on ventilator support, Gladyshevs idea was simple. Could prescribing these drugs to the elderly as preventative measures could give the most vulnerable a better chance of fighting off Covid-19, and prevent them getting to that stage?

Since April, his idea has been taken up by a series of scientists across the US ranging from pharmacologists at Thomas Jefferson University to the Boston-based biotech company resTORbio, who are now testing forms of rapamycin in a series of clinical trials over the coming months.

While rapamycin and metformin are typically known for their clinical uses in cancer and diabetes respectively, the reason why Gladyshev and other longevity scientists think that these drugs could protect the elderly from covid-19 is linked to theories regarding biological age. We typically measure age chronologically based on the number of years a person has been alive, but there is a school of thought that biological age determined by biomarkers varying from DNA expression to the length of telomeres, the tips of chromosomes can vary depending on factors ranging from lifestyle to genetics.

Nir Barzilai, founder of the Institute of Ageing Research at the Einstein College of Medicine in New York, argues that the reason some people are less prone to age-related diseases such as cardiovascular disease, dementia, cancer and infections, is because their biological age is much younger. By the age of 65, half of people in Europe have two diseases or more, but half have less, says Barzilai. For me, this is due to their differing biological ages.

Most of the evidence that drugs might be able to reverse some of the hallmarks of ageing, and thus make an elderly person more resilient to viral infections, comes from studies either in human cells or rodents. This data suggests that rapamycin has the potential to revitalise the bodys natural defence mechanisms within the lungs, stimulating cells such as macrophages which are designed to seek out and remove viruses to work more efficiently.

But there have also been further findings in humans which has given longevity researchers increased confidence that they are on the right lines. Back in March, doctors in Wuhan published a study showing that diabetics taking metformin were much less likely to die of Covid-19 than diabetics not on the drug, an interesting finding which backed up previous epidemiological data showing that it can improve lifespan in diabetics. An earlier clinical trial conducted by resTORbio, using a formulation of rapamycin called RTB101, reported that it could reduce rates of respiratory viral infections in healthy people over 65.

Nevertheless when the Covid-19 pandemic began, few specialists outside of longevity research were aware of the anti-ageing properties of these drugs. At the start of April, Edwin Lam a pharmacology researcher at Thomas Jefferson University was looking at a study from molecular biologists across the US which used computer models to predict which drugs performed best when it came to helping the body remove the virus. To his surprise, rapamycin and metformin ranked top, ahead of many highly touted alternatives such as hydroxychloroquine.

Initially I thought this seemed far-fetched, says Lam. But then I looked further and found that some scientists had previously used a form of rapamycin called Sirolimus to treat people with severe cases of H1N1 bird flu. They saw a reduction in the viral load and better clinical outcomes. It had also shown antiviral activity in a preclinical model of Middle East Respiratory Syndrome. I presented this to my colleagues and we became really intrigued.

Lam has now designed a placebo-controlled clinical trial to see whether rapamycin can reduce the viral load in 20 patients with mild to moderate cases of Covid-19. A similar study is also taking place at the University of Cincinnati. ResTORbio are now looking at whether giving 550 nursing home residents an oral capsule of RTB101 each day over a period of one month, could protect them from becoming severely infected with the virus, and needing hospitalisation.

Nursing home residents have a very high risk of dying from Covid-19, says Joan Mannick, co-founder and chief medical officer of resTORbio. This elevated mortality has made the public acutely aware of the dysfunction of the aging immune system. I think the pandemic has the potential to catalyse interest in therapeutics that target aging biology as a new way to improve the function of aging organ systems.

But other scientists looking at ways to protect the elderly from Covid-19 caution that while they will be monitoring the results of the trials with interest, the evidence regarding the effectiveness of anti-ageing drugs remains limited. Its an interesting approach, but the data will have to speak for itself, says Ofer Levy, who heads the Precision Vaccines Program at Boston Childrens Hospital. Its all about safety and efficacy. Is it safe, how long can they be on it, and then is it effective? But its something to consider.

Levy points to another potentially promising approach for protecting the elderly from Covid-19, vaccines which are specifically designed for older people. These typically contain additional chemicals known as adjuvants to try and kick-start the ageing immune system. Its an approach which was successfully used by British pharma company GlaxoSmithKline to create the Shingrix vaccine in the past five years. This has shown to be highly effective in preventing shingles in people over 50, and Levy is looking to apply this strategy to a Covid-19 vaccine.

One of the ironies of vaccine development is that while over 65s stand to benefit most from immunisation, research has often shown that vaccines against influenza and other infections are at their least effective in the very old. This is thought to be due to changes in the blood which affect the immune response. As we age, the blood plasma changes and we tend to develop a low level of inflammation in our bloodstream, Levy says. Because of this, when you try to immunise someone, you often get an incomplete response to the vaccine.

Instead, Levys group is designing a vaccine which is specifically modelled on older immune systems. Our approach is to take blood donations from elderly volunteers, and then we isolate the immune cells in a dish, he says. We then screen lots of small molecules until we find ones which are like rocket fuel to the immune system, we add them to the vaccine and select the formulations which seem to work best against the coronavirus. This is completely different to normal vaccine development as were actually designing it with the ageing immune system in mind.

He hopes that such a vaccine could be in clinical trials by autumn 2021. Barzilai points out that in the meantime there is some evidence to suggest that supplementary treatment with rapamycin could enhance the effectiveness of the first wave of vaccines when they become available, with Japanese company AnGes hoping to make their Covid-19 vaccine available at the start of next year. Rapamycin has previously been shown to enhance the effectiveness of the influenza vaccine. Im sure that the initial vaccines will not be effective in the elderly, because their designs ignore their immune deficiencies, Barzilai says. But rapamycin could make a difference.

With the increased interest in rapamycin, longevity scientists predict that Covid-19 could prove to be a major boon for the field of anti-ageing research, a sector which has already been benefiting from injections of funding in recent years. Last year Barzilai received $75 million (60.5m) to conduct the TAME clinical trial, looking at whether giving metformin to elderly people over a period of four to five years can give them more years of good health. Gladyshev says that the three Covid-19 clinical trials involving rapamycin could provide a whole host of information regarding its ability to reduce biological age.

However, Barzilai is still frustrated that many within the medical community appear to be unaware of the potential of these drugs. He points to the Wuhan study in March, saying that while similar findings have been observed in Italy and Spain, no one has conducted a clinical trial looking at whether administering metformin to the elderly population in general, can offer protective benefits against Covid-19.

The major problem is that our health organisations are in silo and so ageing is often overlooked as a risk factor in these diseases, he says. For me, the question is why are we not using these two drugs on a wider scale to try and protect the vulnerable, when we already have information that they can offer benefit? Metformin has been used clinically for 60 years, its already known to be safe. If we just focus on stopping the disease in older people, the whole mortality issue would be different, the lockdowns wouldnt need to happen, and the economic impacts would be less as well.

Google got rich from your data. DuckDuckGo is fighting back

The Animal Crossing fans running in-game businesses

Inside the 'bullshit' get-rich-quick world of dropshipping

The secret behind the success of Apple's AirPods

The UK's lockdown rules, explained

Follow WIRED on Twitter, Instagram, Facebook and LinkedIn

Get The Email from WIRED, your no-nonsense briefing on all the biggest stories in technology, business and science. In your inbox every weekday at 12pm sharp.

by entering your email address, you agree to our privacy policy

Thank You. You have successfully subscribed to our newsletter. You will hear from us shortly.

Sorry, you have entered an invalid email. Please refresh and try again.

Read more:
To slow the coronavirus death toll we may need to slow down ageing - Wired.co.uk

Although diaper rash is never something you want to deal with, odds are you've probably fought the good fight with this red, irritating and super common baby and toddler skin ailment more than once during your time as a mama.

Almost every baby suffers through diaper rash at some point during their first few years of life. Prolonged wetness, friction and sensitive baby skin combine into a recipe for disaster when it comes to baby bums and, although generally harmless, diaper rash can be pretty painful and irritating for those little tushes.

Enter diaper cream: A mama's best friend for treatment and prevention of diaper rash, and a staple on the changing table and in every diaper bag.

But with so many to choose from, you need to know which diaper creams actually get the job done. (Because let's be real, you're already spending enough time trying to wrangle your little one for a diaper change in the first place!)

A longstanding favorite among moms, Triple Paste medicated ointment delivers the double whammy of not only healing diaper rash quickly (seriously, mamas, this stuff is magic) but preventing it, as well. It's fragrance-free and hypoallergenic. Plus, a little goes a long way, which means one tub will last for quite a while.

We love a product that can multitask. This ultra-gentle, 100% natural olive oil based gel-to-cream balm not only prevents and knocks out diaper rash, it also works as a nipple balm, cradle cap treatment, lip balm and to soothe eczema. The non-greasy, fragrance-free formula is perfect for even the most sensitive skin of newborns through adults.

Aquaphor is the stuff of dreamsfrom chapped lips to minor cuts + scrapes, there's hardly anything that this magical ointment can't help with. And diaper rash is no exception!

Aquaphor protects baby's skin from wetness, acidity and chafing, and unlike petroleum jelly, creates a barrier over the skin which heals while still enabling the flow of water and air. Added bonusit also works great on mama's dry hands!

Made with 100% natural ingredients from Mongolia, this rich and creamy balm melts right in to protect and soothe baby bums, rolls and creases. The main ingredient, tallow, has been used for centuries by nomadic herders across their harsh climate is ethically and sustainably sourced and provides an unparalleled barrier against moisture and irritation. Bonus: After washing hands a million times a day, this is the only thing that helped my super chapped hands.

How can we not love a diaper rash cream with the slogan "let's kick some rash?" Developed by a pharmacist with four kids who wasn't satisfied with any of the diaper rash creams on the market, Boudreaux's is effective and is made without any harsh chemicals, which is a major win in our book.

This rich and creamy formula might be the most luxurious diaper cream we've ever slathered on a baby bum. It's packed with 18 natural and organic ingredients which have all been carefully selected to nourish and calm irritation. Calendua and chamomile help soothe while things like zinc and shea butter protect against moisture. A little goes a long way!

Desitin takes a spot on our best-of list because it contains the maximum level of zinc oxide available without a prescription, making it a top choice for serious diaper rash. It's thick and rich, creating a strong protective barrier between your baby's diaper and her sensitive skin. It also acts as an anti-inflammatory, reducing the redness and pain that goes along with diaper rash.

This calming salve uses calendulaa flower used to treat inflammation and painto soothe baby bottoms and treat and prevent diaper rash. Infused with other herbs like tea tree oil and shea butter, we love it as one of the more natural diaper rash creams on the market.

Cetaphil is one of our faves for our own skin, so using it on our little ones' sensitive bottoms is a no-brainer. The soothing cream is filled with vitamins and other organic ingredients, and the fresh scent isn't overpowering.

Honest Company is about more than just adorable diapers. Made without phthalates, parabens, fragrances, dyes and other potentially harmful ingredients, this quick-acting diaper rash cream uses zinc oxide and other organic ingredients to relieve even the most stubborn of rashes. It also helps moisturize those tiny bottoms + is easy to apply.

Like a few of our other picks, this European brand also features calendula, along with other natural extracts and oils, to combat diaper rash. Because of its natural makeup, we've found this diaper rash cream to be especially effective for babies with super sensitive skin.

assets.rebelmouse.io

A+D stands the test of time as one of the best diaper rash creams around. The soothing ointment easily glides onto skin, so it's great to apply on-the-regular for continuous protection against a diaper rash.

Maker of some of our favorite baby skin care products around, California Baby has been known for over 20 years as a go-to for safe, natural, and effective products for babies and kids with sensitive skin. This preservative-free, fragrance-free and super concentrated cream uses zinc oxide and other natural ingredients to treat and prevent diaper rash. It's also safe to use with cloth diapers.

We independently select and share the products we loveand may receive a commission if you choose to buy. You've got this.

The rest is here:
13 diaper rash creams that *really* work - Motherly Inc.